Get to know our amazingly versatile and unique RVF® technology
Our Products in Action
Multiplo Multiplex Tests
MedMira’s Multiplo multiplex tests include combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis.
Miriad Research Tools
Miriad includes toolkits to develop new diagnostic tests and commercialized combination tests.
About MedMira
MedMira is dedicated to improving human health by providing the best in rapid diagnostics. Our patented Rapid Vertical Flow Technology™ delivers fast, accurate results for a range of applications—helping care providers and their patients know more, instantly.
MedMira News >
MedMira Announces Progress Update of its REVEALCOVID-19TM Total Antibody test including CE mark
Halifax, Nova Scotia, 21. May, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that it has completed the registration process and affixed the CE mark (Conformité Européene) to its rapid REVEALCOVID-19TM Total Antibody Test.
MedMira Announces Notification Submission to US FDA Emergency Use Authorization
Halifax, Nova Scotia, April 23, 2020, announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing.
MedMira Announces Development of COVID-19 Point-of-Care Antibody Test
Halifax, Nova Scotia, April 15, 2020 –MedMira Announces Update on Development of Point-of-Care Antibody Test
MedMira Reports Second Quarter Results
Halifax, Nova Scotia, March 29, 2018 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended January 31, 2018.
MedMira Announces AGM Results and Stock Option Grant
Halifax, Nova Scotia, February 1, 2018 – MedMira Inc. (MedMira) (TSXV: MIR), held its 2018 Annual General Meeting of Shareholders on January 31, 2018 in Halifax, Nova Scotia.
MedMira Reports First Quarter Results
Halifax, Nova Scotia, December 22, 2017 – MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2017.